Düsseldorf, October 23, 2012 – Rainer Beaujean will join the Gerresheimer AG Management Board on December 1, 2012 and assume the function of CFO on February 1, 2013. The company’s current Chief Financial Officer, Hans-Jürgen Wiecha, is leaving the company on January 31, 2013 to pursue other career opportunities.
The Supervisory Board has appointed Rainer Beaujean to the Gerresheimer AG Management Board as of December 1, 2012. Rainer Beaujean will assume the function of Chief Financial Officer of Gerresheimer AG on February 1, 2013. Until August 2012, Rainer Beaujean was Chief Financial Officer of the Elster Group SE. From 2007 to the end of 2011 he was a member of the Demag Cranes AG Management Board with responsibility for finances. Prior to that he was Chief Financial Officer and Management Board member at T-Online International AG.
“I am delighted that Rainer Beaujean, a highly competent manager, has decided to join us. His vast experience will make a valuable contribution to the company’s future growth path,“ commented Gerhard Schulze, Chairman of the Gerresheimer AG Supervisory Board.
Hans-Jürgen Wiecha, Chief Financial Officer of Gerresheimer AG, will be leaving the company’s service on January 31, 2013 after reaching an amicable mutual agreement with the Supervisory Board. The Supervisory Board has agreed to Hans-Jürgen Wiecha’s premature retirement from the management board. Hans-Jürgen Wiecha joined Gerresheimer AG in 2000 and was appointed to the position of Chief Financial Officer in 2005. In this function, he was responsible for Gerresheimer’s IPO in 2007.
“On behalf of the entire Supervisory Board, I would like to thank Hans-Jürgen Wiecha for his excellent work. He has played a key role in the company’s positive development for many years. I wish him all the best for the future,” said Supervisory Board Chairman, Gerhard Schulze.
About Gerresheimer
Gerresheimer is an internationally leading manufacturer of high-quality specialty products made of glass and plastic for the global pharma and healthcare industry. Our comprehensive portfolio of products extends from pharmaceutical vials to complex drug delivery systems such as syringe systems, insulin pens and inhalers for safe medication dosage and application. Together with our partners, we develop solutions which set standards and have role model status in their respective market sectors.
Our Group realizes revenues of around one billion euros and has around 11.000 employees at 47 locations in Europe, North and South America and Asia. We use first-rate technologies, convincing innovations and targeted investments to systematically consolidate our strong market position.
